Unexpected discovery of new investigational drug for mCRPC
Posted Dec 05 2010 12:00am
Some data about a drug called APR-246 has come to light at the ongoing annual meeting of the American Society of Hematology in Orlando (which is not exactly a prime source for information about prostate cancer).
APR-246, however, is being tested in late stage prostate cancer and in a number of hematologic malignancies (cancers of the blood), so its future development may well depend on exactly how these very different types of cancer respond in the Phase II clinical trial(s).
APR-246 is currently being given to patients as a 2-hour infusion. In the case of prostate cancer, patients have been limited to those with metastatic, castration-resistant prostate cancer (mCRPC). The theory is that APR-246 may be able to restore normal (“wild type”) function of p53 in mutated cancer cells. (This is a common category of mutation in advanced forms of prostate cancer.)
Data about the Phase II clinical trial of APR-246 is not yet available on ClinicalTrials.gov. We assume that enrollment into this trial is likely to be limited (at least initially) to a European population of patients.